Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

• Conditions: Rectal Cancer; Colon Cancer; Liver Metastases

• Registration Number: NCT04213222
• Lead Sponsor: Peking University People's Hospital

Brief Summary

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-12-25
• Study First Submitted QC: 2019-12-25
• Study First Posted: 2019-12-30
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-10
• Last Update Posted: 2020-08-11
• Study Start: 2020-10
• Primary Completion: 2022-06
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Colorectal carcinoma confirmed by pathological result.
2. Liver metastasis confirmed by imaging studies.
3. Treatment of bevacizumab combined with chemotherapy chosen by MDT team.
4. ECOG: 0-2.
5. Normal laboratory studies including liver\renal\bone marrow functions.
6. Expected lifespan more than 3 months.

Read More

Exclusion Criteria

1. Previous treatment of colorectal cancer with liver metastasis.
2. Diagnosed with other malignancies.
3. Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\pregnancy or lactation\chronic heart disease\unable to sustain further treatment.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
estimated ORR	6-8 weeks

Secondary Outcome Measures

Name	Time	Method
estimated OS	3 years
estimated PFS	3 years

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Peking, Beijing, China